Hovilpri (pritelivir)

Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults

Also known as AIC316

Manufacturer: Asahi Kasei Therapeutics
Regulatory submission: NDA submitted February 2026 and approved October 2026
Launch: Anticipated before the end of 2026
Last updated: October 11, 2026

Section

Product information and disease description Product description

Product information

283 evidence topics · 92 sources

Generic, brand name and therapeutic class of product10 evidence topics · 11 sources
Dosage forms and strengths8 evidence topics · 4 sources
Average sales price and wholesale acquisition cost5 evidence topics · 3 sources
American hospital formulary service (AHFS), or other drug classification3 evidence topics · 3 sources
Indication8 evidence topics · 5 sources
Pharmacology81 evidence topics · 32 sources
Contraindications/Warnings/Precautions/Adverse effects15 evidence topics · 2 sources
Special populations25 evidence topics · 7 sources
Drug/Drug, drug/disease interactions25 evidence topics · 7 sources
Dosing and administration21 evidence topics · 9 sources
Access and distribution16 evidence topics · 14 sources
Co-prescribed/Concomitant therapies13 evidence topics · 5 sources
Product comparison53 evidence topics · 30 sources

Effect of pritelivir on quality measures

No evidence found.